



U.S. Patent No. 8,153,162; 8,182,902; 8,182,840; 8,182,841; 8,440,235; 8,455,009; 8,460,714; 9,161,955; 9,161,956; 9,198,939; 9,724,370; 9,750,771

### **PRODUCT INSERT**

### **DESCRIPTION**

**CLARIX FLO** is a sterile, particulate human amniotic membrane and umbilical cord tissue product that is aseptically processed in compliance with current Good Tissue Practices (cGTP) from the same donated human tissue (placenta) after determination of eligibility and placenta/cord suitability. There is no pooling of tissues from different donors during recovery or throughout the manufacturing process. **CLARIX FLO** does not contain living cells. **CLARIX FLO** is terminally sterilized via gamma sterilization with a Sterility Assurance Level (SAL) of 10-6.

### **INTENDED USE**

 CLARIX FLO is for single use only in one patient by a licensed physician (DPM, MD, or DO) or a qualified medical professional with relevant clinical experience such as a nurse or PA.

### **PRECAUTIONS**

- Do not use CLARIX FLO if the packaging is damaged Contact Amniox Medical, Inc. immediately if there is any abnormality observed in any area (e.g. labeling, packaging, shipping, missing information, etc.).
- Once the outer foil pouch is opened, CLARIX FLO shall either be transplanted or otherwise discarded.
- Suspend and remove CLARIX FLO only at the time of use.
- Do not re-sterilize the product. Do not autoclave before use.

### **WARNINGS**

As with the use of any human tissue, the possibility of infectious agent transmission cannot be completely eliminated although all screening and microbial testing results were satisfactory for this donor.

# STORAGE

It is the responsibility of the Tissue Dispensing Service, Tissue Distribution Intermediary, and/or End-User Clinician to maintain tissue intended for transplantation in appropriate storage conditions prior to further distribution or transplant.

Upon receipt, ensure the validated time on the shipper has not expired. Remove the product and store accordingly until use:

LOCATION & TEMPERATURE	USE AFTER RECEIPT
Ambient Room Temperature $0^{\circ}C \rightarrow 38.0^{\circ}C$ $(32.0^{\circ}F \rightarrow 100.4^{\circ}F)$	Until the expiration date printed on outer product packaging (shelf-life is 2 years from date of manufacture)

# INSTRUCTIONS

- Open the pouch to retrieve the CLARIX FLO vial. Vial can be delivered to a sterile field.
- 2. To suspend for injection, first remove the cap from the vial. Aseptically transfer approximately 0.5-2.0 mL of normal saline or sterile USP injection water into the vial with an 18-25 gauge needle. Shake the vial for at least 45 seconds to achieve a homologous mixture. Aseptically withdraw the mixture with a syringe and an 18-25 gauge needle.
- 3. After transplantation, complete the Donor and Recipient Information (DRI) Card and return to Amniox Medical, Inc.

- 1																	
- :																	
- 1																	
- 1																	
- 1																	
- 1																	
- 1			_														
			1)		•		NI.		h	SI L		~					
				lac		UЛ	л	1 7	11 )+	<del>-</del> 11 [	⊐∺	! ₩					
- 1			•	. ~ ~													
- 1																	
- 1																	
- 1																	
- 1																	
- 1																	
- 1																	
- 1																	
٠,																	
- 1																	
- 3																	
- 1																	
- 1																	

## **DONOR ELIGIBILITY AND SUMMARY OF RECORDS**

- This tissue was procured from a donor determined to be eligible based on the results of testing. HCT/P donor eligibility and placenta suitability, which is based on the results of donor testing at delivery for infectious, malignant, neurological & auto-immune diseases and for other exposures or social habits, has been determined and documented by TissueTech, Inc.
- A blood specimen, drawn within ± 7 days of donation, has undergone serological testing by a laboratory registered with the FDA to perform donor testing and certified to perform such testing on human specimens in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and 42 CFR Part 493, or that has met equivalent requirements as determined by the Centers for Medicare and Medicaid Services (CMS). The donor has been tested for the following infectious diseases and results were non-reactive:

110/40100/04 19 1	
— HIV-1 & HIV-2 Antibody	<ul> <li>Hepatitis C Antibody (HCVAb)</li> </ul>
— HIV-1 (RNA-NAT)	<ul> <li>Hepatitis C Virus (HCV, RNA-NAT)</li> </ul>
— Hepatitis B Surface Antigen (HBsAg)	— Syphilis (RPR)
<ul> <li>Hepatitis B Core Antibody (HBcAb)</li> </ul>	- HTLV I & II Antibody (HTLV I/II Ab)
- Hepatitis B (HBV, DNA-NAT)	<ul> <li>West Nile Virus (WNV, RNA-NAT)</li> </ul>

- This tissue has been deemed eligible for transplantation based on acceptable testing, serological and microbial test results.
- A Certificate of Compliance regarding the manufacturing, storage, shipping and tracking controls for Amniox Medical products is available upon request.

## **RECIPIENT RECORDS**

It is the responsibility of the Tissue Dispensing Service, Tissue Distribution Intermediary, and/or End-User Clinician to maintain records for the purpose of tracing tissue post-transplantation. The transplanting entity should document the disposition (transplanted or discarded) on the Donor and Recipient Information Card (DRI), attach one of the provided product tracking labels to the DRI and mail to Amniox Medical. Attach the remaining labels in patient and hospital records.

## **CUSTOMER FEEDBACK**

Within the United States: Report any customer feedback, including complaint, error or accident notification promptly to Amniox Medical at (888) 709-2140.

Outside of the United States: Report feedback to your local tissue provider.

### **ADVERSE EVENT**

**Phone**: (888) 709-2140 **Fax**: (305) 675-3262

The FDA requires that information be supplied to the product manufacturer for mandatory reporting of adverse events. Possible significant adverse events include microbial infection and transmission of viral disease. The doctor is responsible for immediately reporting any adverse event potentially attributable to the use of CLARIX FLO to Amniox Medical.

For Adverse Events, complete the following section. Notify via:

Email: Customerfeedback@amnioxmedical.com
Serial Number:
Expiration Date: / /
Doctor Name:
Facility Name:
Transplant Date: / /
Diagnosis/Procedure:
Site of Use:
Point of Contact's Name:
Point of Contact's Phone Number://
Date Adverse Event was Reported:
Type of Adverse Event:  Microbial Infection Transmission of Viral Disease Other
Describe the Adverse Event:



Manufactured for Amniox Medical, Inc. by TissueTech, Inc. 8305 NW 27th St, Suite 101, Doral, Florida 33122 USA (888) 296-8858